Correlation of plasma anti-tuberculosis drug levels with subsequent development of hepatotoxicity

International Journal of Tuberculosis and Lung Disease

Volumn 18, Issue 2, 2014, Pages 188-195

  Satyaraddi, A ^a   Velpandian, T ^a   Sharma, Surendra K ^a   Vishnubhatla, S ^a   Sharma, A ^b   Sirohiwal, A ^a   Makharia, G K ^c   Sinha, S ^a   Biswas, A ^a   Singh, S ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b MEDICAL UNIVERSITY PLEVEN   (Bulgaria)

^c Departments of Gastroenterology   (India)

Author keywords

Anti tuberculosis drugs; Drug induced hepatotoxicity; Plasma drug levels; Rifampicin

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN;

ABDOMINAL PAIN; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG BLOOD LEVEL; DRUG INDUCED DISEASE; DRUG METABOLISM; DRUG TOLERABILITY; FEMALE; HAZARD RATIO; HUMAN; JAUNDICE; LIVER TOXICITY; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; PRIORITY JOURNAL; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; TUBERCULOSIS; VOMITING;

ADULT; ANTITUBERCULAR AGENTS; AREA UNDER CURVE; CASE-CONTROL STUDIES; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; DRUG THERAPY, COMBINATION; DRUG-INDUCED LIVER INJURY; FEMALE; HUMANS; ISONIAZID; MALE; METABOLIC CLEARANCE RATE; PROSPECTIVE STUDIES; PYRAZINAMIDE; RIFAMPIN; RISK FACTORS; TUBERCULOSIS;

EID: 84892597477     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.13.0128     Document Type: Article

References (29)

1. Schaberg T, Rebhan K, Lode H. Risk factors for side-effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis. Eur Respir J 1996; 9: 2026-2030.
2. Black M, Mitchell J R, Zimmerman H J, Ishak K G, Epler G R. Isoniazid-associated hepatitis in 114 patients. Gastroenterology 1975; 69: 289-302.
3. Dash L A, Comstock G W, Flynn J P. Isoniazid preventive therapy: retrospect and prospect. Am Rev Respir Dis 1980; 121: 1039-1044.
4. Sharma S K, Balamurugan A, Saha P K, Pandey R M, Mehra N K. Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during anti-tuberculosis treatment. Am J Respir Crit Care Med 2002; 166: 916-919.
5. Singh J, Arora A, Garg P K, Thakur V S, Pande J N, Tandon R K. Anti-tuberculosis treatment-induced hepatotoxicity: role of predictive factors. Postgrad Med J 1995; 71: 359-362.
6. Steele M A, Burk R F, DesPrez R M. Toxic hepatitis with isoniazid and rifampin. A meta-analysis. Chest 1991; 99: 465-471.
7. Saukkonen J J, Cohn D L, Jasmer R M, et al. An offi cial ATS statement: hepatotoxicity of anti-tuberculosis therapy. Am J Respir Crit Care Med 2006; 174: 935-952.
8. Sharma S K. Anti-tuberculosis drugs and hepatotoxicity. Infect Genet Evol 2004; 4: 167-170.
9. Yew W W, Leung C C. Anti-tuberculosis drugs and hepatotoxicity. Respirology 2006; 11: 699-707.
10. Karmakar S, Sharma S K, Vashishtha R, et al. Clinical characteristics of tuberculosis-associated immune reconstitution infl ammatory syndrome in North Indian population of HIV/ AIDS patients receiving HAART. Clin Dev Immunol 2011; 2011: 239021.
11. Sharma S K, Mohan A, Pande J N, Prasad K L, Gupta A K, Khilnani G C. Clinical profile, laboratory characteristics and outcome in miliary tuberculosis. QJM 1995; 88: 29-37.
12. Sharma S K, Solanki R, Mohan A, Jain N K, Chauhan L S. Outcomes of Category 3 DOTS treatment in immunocompetent patients with tuberculosis pleural effusion. Int J Tuberc Lung Dis 2012; 16: 1505-1509.
13. Prakash J, Velpandian T, Pande J N, Gupta S K. Serum rifampicin levels in patients with tuberculosis: effect of P-glycoprotein and CYP3A4 blockers on its absorption. Clin Drug Investig 2003; 23: 463-472.
14. Song S H, Jun S H, Park K U, et al. Simultaneous determination of fi rst-line anti-tuberculosis drugs and their major metabolic ratios by liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 2007; 21: 1331-1338.
15. Pande J N, Singh S P, Khilnani G C, Khilnani S, Tandon R K. Risk factors for hepatotoxicity from anti-tuberculosis drugs: a case-control study. Thorax 1996; 51: 132-136.
16. Sharma S K, Singla R, Sarda P, et al. Safety of 3 different reintroduction regimens of anti-tuberculosis drugs after development of anti-tuberculosis treatment-induced hepatotoxicity. Clin Infect Dis 2010; 50: 833-839.
17. Grosset J, Leventis S. Adverse effects of rifampin. Rev Infect Dis 1983; 5: 440-450.
18. Capelle P, Dhumeaux D, Mora M, Feldmann G, Berthelot P. Effect of rifampicin on liver function in man. Gut 1972; 13: 366-371.
19. Acocella G. Clinical pharmacokinetics of rifampicin. Clin Pharmacokinet 1978; 3: 108-127.
20. Polasa K, Krishnaswamy K. In vitro studies on protein binding of rifampicin. Indian J Pharmac 1987; 19: 225-229.
21. Ruslami R, Nijland H M, Alisjahbana B, Parwati I, van Crevel R, Aarnoutse R E. Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients. Antimicrob Agents Chemother 2007; 51: 2546-2551.
22. Long M W, Snider D E Jr, Farer L S. US Public Health Service Cooperative trial of three rifampin-isoniazid regimens in treatment of pulmonary tuberculosis. Am Rev Respir Dis 1979; 119: 879-894.
23. Mitchell J R, Long M W, Thorgeirsson U P, Jollow D J. Acetylation rates and monthly liver function tests during one year of isoniazid preventive therapy. Chest 1975; 68: 181-190.
24. Mitchell J R, Thorgeirsson U P, Black M, et al. Increased incidence of isoniazid hepatitis in rapid acetylators: possible relation to hydranize metabolites. Clin Pharmacol Ther 1975; 18: 70-79.
25. Sarma G R, Immanuel C, Kailasam S, Narayana A S, Venkatesan P. Rifampin-induced release of hydrazine from isoniazid. A possible cause of hepatitis during treatment of tuberculosis with regimens containing isoniazid and rifampin. Am Rev Respir Dis 1986; 133: 1072-1075.
26. US Public Health Service. Hepatic toxicity of pyrazinamide used with isoniazid in tuberculous patients. Am Rev Respir Dis 1969; 59: 13.
27. Centers for Disease Control and Prevention, American Thoracic Society. Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection - United States, 2003. MMWR Morb Mortal Wkly Rep 2003; 52: 735-739.
28. Diehl A M. Cytokine regulation of liver injury and repair. I mmunol Rev 2000; 174: 160-171.
29. Williams G M, Iatropoulos M J. Alteration of liver cell function and proliferation: differentiation between adaptation and toxicity. Toxicol Pathol 2002; 30: 41-53.